Results 121 to 130 of about 399,367 (396)

Acod1 Promotes PAD4 Ubiquitination via UBR5 Alkylation to Modulate NETosis and Exert Protective Effects in Sepsis

Advanced Science, EarlyView.
In this study, Acod1 knockout in CLP mice significantly increases peripheral blood NET levels, exacerbating inflammation, organ damage, and reducing survival. Further research shows that UBR5 interacts with PAD4, a key NET formation protein. Acod1/itaconate (ITA) enhances the enzymatic activity of UBR5 by alkylating the Cys2768 site, promoting the K48 ...
Huifan Liu, Guoqing Jing, Shujuan Wu, Min Yuan, Yingyue Dong, Xue Chen, Huimin Zhou, Hailong Gong, Jing Zuo, Xiaojing Wu, Xuemin Song   +10 more
wiley   +1 more source

Relation of common ABL kinase domain mutations with resistance to Tyrosine Kinase Inhibiters in patients with Chronic Myeloid Leukemia in Middle Euphrates of Iraq [PDF]

, 2020
Background: Chronic myeloid leukemia (CML) is a hematopoietic stem cell disease, associated with a reciprocal translocation between chromosomes 9 and chromosome 22, lead to the formation of the BCRABL fusion gene (Philadelphia chromosome).
Musawi, Mohammed Sadeq Mahdi Al-
core  

Transcriptional activation of the miR-17-92 cluster is involved in the growth-promoting effects of MYB in human Ph-positive leukemia cells. [PDF]

, 2018
MicroRNAs, non-coding regulators of gene expression, are likely to function as important downstream effectors of many transcription factors including MYB. Optimal levels of MYB are required for transformation/maintenance of BCR-ABL-expressing cells.
Blandino, Giovanni, Calabretta, Bruno, Cordone, Iole, De Dominici, Marco, Korita, Etleva, Lulli, Valentina, Magenta, Alessandra, Marchesi, Francesco, Mengarelli, Andrea, Pelosi, Andrea, Pisani, Francesco, Regazzo, Giulia, Rizzo, Maria G., Sacconi, Andrea, Spagnuolo, Manuela, Strano, Sabrina   +15 more
core   +3 more sources

Bilateral vision loss as initial presentation of chronic myeloid leukemia in a young adult: A case report and review of the literature

American Journal of Ophthalmology Case Reports, 2022
Purpose: To report a case of bilateral vision loss as the primary presenting symptom of chronic myeloid leukemia in a young adult. Observations: The 28-year-old male patient presented to clinic with visual acuity of 20/200 in both eyes after several ...
Nathan J. Brown, Erin A. Kaya, Jonathan G. Haymore, Lauren V. Gioia   +3 more
doaj  

Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia

Haematologica, 2013
Chronic myelomonocytic leukemia is a heterogeneous disease with multifactorial molecular pathogenesis. Various recurrent somatic mutations have been detected alone or in combination in chronic myelomonocytic leukemia.
Sarah Abu Kar, Anna Jankowska, Hideki Makishima, Valeria Visconte, Andres Jerez, Yuka Sugimoto, Hideki Muramatsu, Fabiola Traina, Manuel Afable, Kathryn Guinta, Ramon V. Tiu, Bartlomiej Przychodzen, Hirotoshi Sakaguchi, Seiji Kojima, Mikkael A. Sekeres, Alan F. List, Michael A. McDevitt, Jaroslaw P. Maciejewski   +17 more
doaj   +1 more source

Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.

Journal of Clinical Oncology, 2019
PURPOSE Colony-stimulating factor-3 receptor (CSF3R)-T618I is a recurrent activating mutation in chronic neutrophilic leukemia (CNL) and to a lesser extent in atypical chronic myeloid leukemia (aCML) resulting in constitutive JAK-STAT signaling.
K. Dao, J. Gotlib, Michael Deininger, S. Oh, J. Cortes, R. Collins, E. Winton, Dana R Parker, Hyunjung Lee, Anna Reister, Schultz, S. Savage, Stevens, Chase Brockett, N. Subbiah, R. Press, Philipp W. Raess, Michael J. Cascio, J. Dunlap, Yiyi Chen, C. Degnin, Julia E. Maxson, C. Tognon, T. Macey, B. Druker, J. Tyner   +25 more
semanticscholar   +1 more source

USP10 Inhibits Ferroptosis via Deubiquinating POLR2A in Head and Neck Squamous Cell Carcinoma

Advanced Science, EarlyView.
This study identifies USP10 as a novel deubiquitinase that antagonizes ferroptosis in head and neck squamous cell carcinoma (HNSCC). Mechanistically, USP10 directly stabilizes POLR2A protein through post‐translational deubiquitination, enabling POLR2A‐mediated transcriptional activation of SLC7A11, a key ferroptosis inhibitor.
Diekuo Zhang, Xueying Wang, Shanhong Lu, Yan Gao, Gangcai Zhu, Guo Li, Zongnan Yu, Junwei Hou, Helei Yan, Wenhui Yuan, Xin Zhang, Mien‐Chie Hung, Zhifeng Liu, Yong Liu   +13 more
wiley   +1 more source

BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia [PDF]

, 2012
MECOM oncogene expression correlates with chronic myeloid leukaemia (CML) progression. Here we show that the knockdown of MECOM (E) and MECOM (ME) isoforms reduces cell division at low cell density, inhibits colony-forming cells by 34% and moderately ...
Alzuherri, Aytekin, Barjesteh van Waalwijk van Doorn-Khosrovani, Bartholomew, Ben-Neriah, Bianchini, Carapeti, Carlesso, Daghistani, De Weer, Elrick, Fabbro, Fears, Gerhardt, Goyama, Hamilton, Henzan, Hoyt, Huang, Håkansson, Irvine, Jørgensen, Khanna-Gupta, Kilbey, Konopka, Kurzrock, Kustikova, Lin, Livak, Lugthart, Lugthart, Melo, Mitani, Morishita, Morishita, Morishita, Morishita, Nakamura, Nunoda, O'Hare, Ogawa, Paquette, Pendergast, Russell, Sellers, Skorski, Smith, Stevens-Kroef, Suzukawa, Valent, Wetzler, Wieser, Wimmer, Yuasa   +53 more
core   +1 more source

Management of Chronic Myeloid Leukemia in Advanced Phase

Frontiers in Oncology, 2019
Management of chronic myeloid leukemia (CML) in advanced phases remains a challenge also in the era of tyrosine kinase inhibitors (TKIs) treatment. Cytogenetic clonal evolution and development of resistant mutations represent crucial events that limit ...
M. Bonifacio, F. Stagno, L. Scaffidi, M. Krampera, F. Di Raimondo   +4 more
semanticscholar   +1 more source

RIG‐I‐Inducing Small Molecules Potently Inhibit HMA‐Resistant AML Through Igniting the Overloaded dsRNA Arsenal

Advanced Science, EarlyView.
This study reveals a novel mechanism of resistance to DNA hypomethylating agents (HMAs) in acute myeloid leukemia (AML), and identifies all‐trans retinoic acid (ATRA) and tamibarotene (TAM) as potent agents that overcome HMA resistance by reactivating the interferon anticancer immune response. The findings offer promising therapeutic strategies for HMA‐
Xueqin Chen, Jiaqi Wu, Yuntong Li, Jiayu Huang, Xiangqin Weng, Jiale Wu, Shujun Xiao, Huaxin Song, Zhengyuan Wang, Ni Yan, Fangfang Shi, Derun Zheng, Kai Tan, Hesong Zhang, Jingyi Cui, Wen Wu, Wei Wu, Sujiang Zhang, Min Lu   +18 more
wiley   +1 more source